plays an vital role in the male phenotype and PCa biology. PCa was originally identified as an androgen-dependent tumor, and its growth and survival were found to be controlled by AR signaling. 4 Androgen deprivation therapy is effective for inhibiting PCa growth by initially suppressing AR activity. 5 However, this treatment is more likely to lead to recurrence of prostate cancer, and relapsed prostate cancer is not responsive to androgen deprivation therapy. 6 Despite the loss of response to antiandrogens, data suggest that AR signaling continues to play a role in castration-resistant prostate cancer.
The EphA3 gene is AR-regulated and contains an AR genomic binding site that was confirmed by our previous research, and our previous study identified EphA3 as the first hypomethylated gene in a differentially methylated gene map. The mRNA level of EphA3 differs significantly (192-fold) between androgen-independent PCa and androgen-dependent PCa cell lines according to a DNA methylation chip-based study. 7 Our previous data showing that the EphA3 gene is AR-regulated and contains an AR genomic binding site was obtained using chromatin immunoprecipitation (ChIP) in combination with direct sequencing (ChIP-seq). Singh et al demonstrated that EphA3 is significantly upregulated in castration-resistant PCa cells, which exhibit differential expression during androgen-independent progression. 8 These results prompted the present study focusing on the correlation between EphA3 and AR in the malignant behavior of PCa.
Eph receptors (Ephs) are the largest family of receptor tyrosine kinases with fourteen receptors divided into two subfamilies (EphAs and EphBs); these receptors are associated with angiogenesis and tumor vasculature in various human cancers. 9 EphA3 is highly expressed in the brain, kidneys, heart, and lungs during embryonic development and then declines to a low level in adults. However, EphA3 expression is also elevated in a wide range of malignancies, including hepatocellular carcinoma, 10 glioblastoma, 11 gastric cancer, 12, 13 and melanoma, 14 and is correlated with tumorigenicity, tumor angiogenesis, cancer progression, and poor prognosis.
10-14
The EphA3-specific monoclonal antibody IIIA4 was also found to have antitumor effects in EphA3-expressing leukemic xenografts.
15
KB004, a monoclonal antibody targeting EphA3, has been used in a multicenter phase I study of human hematologic malignancies.
16
Accordingly, EphA3 has received more attention as a promising target for the treatment of several cancers. 17 
| MATERIAL S AND ME THODS

| Patient samples
Using a retrospective study design, PCa and adjacent benign tissues Biochemical recurrence was defined as a PSA concentration of ≥0.2 ng/mL.
All of the stained sections were reviewed by two pathologists (XX, and BH). The follow-up protocol at the institution included a clinical visit, physical examination, and contrast-enhanced CT at day 7, month 3, month 6, and every 6 months thereafter.
| Immunohistochemical analysis technique
The tissue sections were incubated with a mouse monoclonal an- was used instead of the primary antibody as the negative control.
| Interpretation of the immunostaining results
The sections were viewed by two pathologists without knowledge of the clinical records of the patients, and any disagreements were resolved by reassessment and consensus. A previously developed semiquantitative system to determine EphA3 expression was used.
A staining index (SI; values 0-12) was calculated as a product of staining intensity (no staining = 0, light yellow/weak staining = 1, yellowish brown/moderate staining = 2, brown/strong staining = 3) and proportion of positive cells (0%-5% = 0, 6%-25% = 1, 26%-50% = 2, 51%-75% = 3;>75% = 4). Cutoff points for SI categories were based on median values. 
| Statistical analysis
The statistical analysis was performed using SPSS (v20.0; IBM, Inc, Armonk, NY, USA) software. Significant differences were calculated using the chi-squared test. Overall survival (OS) was used to evaluate the prognosis. The survival curves were obtained by the KaplanMeier method and compared with the log-rank test. The multivariate model used a Cox regression analysis. The statistical significance was set at P < 0.05 or 0.01 as indicated.
| RE SULTS
| Clinical data
The median age at diagnosis for the 64 patients was 73 years (range, During the study period, 13 patients died of their cancer.
| EphA3 and AR protein expression in human PCa
Positive staining of the AR protein was found in the nucleus, EphA3 was located in the nucleus and cytoplasm of the PCa tissues, and the adjacent normal prostate tissues all showed faint staining according to the IHC of Table 2 ).
| Association of clinicopathological parameters with EphA3 and AR expression
EphA3 and AR expression levels and their association with the clinical characteristics of the 64 PCa tissue samples are shown in Table 2 . The high levels of EphA3 and AR expression in the PCa tissue samples were both correlated with the pathological stage, bladder and rectal invasion, distant metastasis, and preoperative PSA level (both P < 0.05). Neither correlated with age nor seminal vesicle invasion (both P > 0.05). Only high level of EphA3 was related to biochemical recurrence (χ 2 = 11.803, P = 0.001, chi-squared test), and high AR expression was related to the Gleason score (χ 2 = 6.223, P = 0.013, chi-squared test).
TA B L E 1 Characteristics of patients with prostate cancer
| EphA3 and AR expression in the prognosis of PCa
The Kaplan-Meier survival curves of EphA3 and the AR are shown in Figure 2 .
The survival time of patients with high level of AR expression was significantly shorter than that of patients with a low AR level (P = 0.001, log-rank test). The high level of EphA3 in PCa patients suggests a poor prognosis (P = 0.014, log-rank test). In the Cox regression analysis of OS (Table 3) , biochemical recurrence, distant metastasis, and the final scores of EphA3 and AR expression were significantly correlated with the prognosis of PCa (P < 0.05).
Moreover, the final scores of EphA3 expression were confirmed as an independent prognostic indicator of poor OS in multivariate analysis.
| Correlation of expression
The EphA3 and AR were positively correlated in PCa based on protein expression by analyzing the final scores of EphA3 and AR expression (r = 0.571, P = 0.001, Spearman correlation test).
| D ISCUSS I ON
Because of the limited prognostic data for EphA3 in PCa, we investigated for the first time the association between EphA3 and AR expression along with PCa prognosis using human PCa and adjacent tissues. Positive staining of the AR protein was found in the nucleus, and EphA3 was located in the nucleus and cytoplasm of the PCa tissues, and all adjacent normal prostate tissues showed faint staining.
The same phenomenon regarding EphA3 expression was also reported by Wu et al, 22 who showed using a human PCa tissue microarray that EphA3 is overexpressed in PCa specimens and that EphA3 is highly expressed in androgen-independent and metastatic cell lines. The relationship between EphA3 and AR expression and the clinical characteristics of PCa were further investigated in the present study. The results showed that both proteins were correlated with pathological stage, bladder and rectal invasion, distant metastasis, and the preoperative PSA level but were not correlated with age or seminal vesicle invasion. Biochemical recurrence was only related to high EphA3 expression levels, and the Gleason score was only related to a high level of AR expression. The high EphA3 level has also been correlated with histological grade, the invasion depth, distant metastasis and TNM stage in colorectal cancer 26 and gastric cancer. 13 A high expression level of EphA3 has been correlated with a high invasive capacity in hepatocellular cancer 10 and mesenchymal glioblastoma. 11 Regarding PCa, EphA3 is a significantly upregulated gene in androgen-independent cells, 8 and this phenomenon might be due to a mechanism of gene amplification or DNA methylation. 27 In addition, Diao et al found that EphA3 expression was induced by the interaction of the AR with SP1 transcription factor. 23 These findings suggest that there is some correlation between EphA3 and PCa progression.
A significant relationship between EphA3 expression and OS was observed. Using a hospital-based retrospective analysis, the prognostic study showed that patients with high levels of EphA3 and AR expression had significantly shorter survival times. A high EphA3 level independent of other prognostic factors was associated with a lower OS rate. In multivariate analysis, the biochemical recurrence, distant metastasis, EphA3 and AR expression were significantly associated with the prognosis of PCa and were independent prog- and AR according to the Spearman correlation test using the sum staining scores of the immunohistochemistry analysis and found a positive correlation between these factors. Diao et al found that the EphA3 mRNA and protein levels were both elevated by the hormone DHT in a dose-and time-dependent manner accompanied by increased AR expression. The overexpression of pEGFP-AR in 22Rv1 cells significantly increased the EphA3 level, whereas AR knockdown with small interfering RNA (siRNA) specific for the AR (siAR) markedly decreased the expression of EphA3. 23 Another study showed that prostate androgen induces the prostate leucine zipper genepromoted expression of EphA3. 22 Overall, these results suggest that EphA3 expression is affected by the AR or possibly factors in the AR signaling pathway. The exact mechanism of this phenomenon is unclear and needs to be studied further.
| CON CLUS IONS
Given the findings described above, EphA3 plays an important role both individually and together with other factors in the progression and prognosis of PCa. EphA3 may be a useful prognostic biomarker of PCa, with the presence of EphA3 suggesting a poor outcome and decreased survival. EphA3 affects the prognosis of PCa, potentially through the AR or a related pathway factor.
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